HomeAI · summaries
Storia in 20 fonti
Médicaments anti-obésité : Novo Nordisk accuse son rival Eli Lilly de publicité mensongère
Aux Etats-Unis, les deux laboratoires ne lésinent pas sur les dépenses pour diffuser de vastes campagnes publicitaires sur les ondes, le petit écran, les réseaux sociaux et jusque dans les stades lors des grandes compétitions sportives nationales.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
mediapart.fr
Traitement anti-obésité: Novo Nordisk poursuit Eli Lilly aux Etats-Unis pour « publicité mensongère »
Le géant pharmaceutique danois Novo Nordisk, fabricant des traitements anti-obésité et anti-diabète Wegovy et Ozempic, a annoncé mardi qu’il poursuivait en justice aux Etats-Unis…
- ·
biopharmadive.com
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…
- ·
politiken.dk
Novo Nordisk sagsøger sin største konkurrent
Novo Nordisk mener, at Eli Lilly har benyttet sig af vildledende markedsføring i USA og går nu rettens vej.
- ·
economictimes.indiatimes.com
Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug
Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its…
- ·
france24.com
Pharma heavyweights clash over anti-obesity drug ads
Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing…
- ·
lecho.be
Novo Nordisk intente un procès à Eli Lilly pour publicité mensongère sur ses traitements anti-obésité
Le duel entre les leaders du marché de l'anti-obésité se poursuit devant les tribunaux américains. Le fabricant du Wegovy a saisi la justice, estimant que les publicités pour…
- ·
fiercepharma.com
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads
Novo Nordisk has accused rival Eli Lilly of runnin | Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public…
- ·
wiwo.de
Pharmaindustrie: Novo Nordisk verklagt US-Rivalen Eli Lilly
Das dänische Unternehmen sieht sich in einer Werbung seines US-Konkurrenten falsch dargestellt und klagt. Worum es in den Streit geht.
- ·
milanofinanza.it
Novo Nordisk porta Eli Lilly in tribunale: pubblicità ingannevole sui farmaci anti-obesità | MilanoFinanza News
La casa farmaceutica danese accusa la rivale americana di aver promosso Zepbound e Mounjaro con confronti «falsi e fuorvianti» rispetto a Wegovy e Ozempic. Nel mirino una campagna…
- ·
eluniversal.com.mx
Novo Nordisk, fabricante de Ozempic y Wegovy, demanda a Eli Lilly; acusa publicidad engañosa sobre medicamentos contra obesidad y diabetes
La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound
- ·
dw.com
Ozempic maker sues US rival over ad campaign
Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.
- ·
forbes.it
Novo Nordisk fa causa alla rivale Eli Lilly per pubblicità ingannevole sui farmaci GLP-1
Novo Nordisk cita in giudizio Eli Lilly: sotto accusa campagne basate su dati superati per esagerare l'efficacia dei farmaci GLP-1
- ·
nu.nl
Novo Nordisk klaagt concurrent Eli Lilly aan wegens misleidende reclame
Het Deense farmacieconcern Novo Nordisk heeft in de Verenigde Staten een rechtszaak aangespannen tegen Amerikaanse aartsrivaal Eli Lilly in de Verenigde Staten. Volgens het…
- ·
expansion.com
Novo Nordisk demanda a Lilly por publicidad enga�osa en su batalla contra la obesidad
La demanda de Novo Nordisk, interpuesta en un juzgado de Nueva Jersey (EEUU), acusa a Lilly de utilizar datos cl�nicos anticuados en una campa�a para sostener que Zepbound, el...
- ·
lavanguardia.com
Guerra por la obesidad: Novo Nordisk (Ozempic) demanda a Eli Lilly por publicidad engañosa
La farmacéutica danesa acusa a su rival estadounidense de utilizar estudios desactualizados para promocionar sus alternativas Zepbound y Mounjaro
- ·
milenio.com
Novo Nordisk demanda a Eli Lilly por publicidad engañosa de Ozempic
Novo Nordisk acusa a Eli Lilly ante un tribunal de EE.UU. por publicidad engañosa sobre la eficacia de sus medicamentos para adelgazar Zepbound y Wegovy.
- ·
channelnewsasia.com
Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads
Novo Nordisk said Eli Lilly's ads uses outdated research and leave out important information, which could mislead consumers.
- ·
endpoints.news
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
Novo Nordisk sues Eli Lilly, alleging its Zepbound ads misleadingly compare doses against outdated Wegovy data.
- ·
axios.com
Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads
The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly, accusing its arch-rival of misleading advertising.
- ·
valor.globo.com
Novo Nordisk leva Eli Lilly à Justiça por publicidade
As acusações são sobre propaganda falsa em remédio para emagrecimento